SA
RGEN logo
Repligen Corporation(RGEN)
Updated 2:38 PM ETAbout this dataData status
$170.97▲8.79 (5.42%)

Repligen Corporation specializes in bioprocessing technologies for the global biopharmaceutical industry, providing critical products such as filtration systems and chromatography resins. Its competitive position is strengthened by a diverse product portfolio and a focus on high-growth markets, particularly in North America and Europe.

HealthcareMedical - Instruments & Suppliesmoderate - the company has a mix of fixed and variable costs, with significant operational efficiencies gained through scale in production.

Business Overview

01Bioprocessing products - approximately 70%
02Chromatography resins - approximately 20%
03Other bioprocessing services - approximately 10%

Repligen generates revenue through the sale of bioprocessing equipment and consumables, leveraging strong relationships with biopharmaceutical manufacturers. Its competitive advantages include proprietary technologies and a robust R&D pipeline that allows for innovation in a rapidly evolving market.

What Moves the Stock

Demand for bioprocessing technologies driven by increased biopharmaceutical production

Regulatory changes impacting the biopharma industry

Mergers and acquisitions activity within the biotech sector

New product launches and innovations in bioprocessing

Watch on Earnings
Revenue growth rateGross margin percentageOperating cash flow

Risk Factors

Technological disruption from emerging bioprocessing competitors

Regulatory changes that could impact product approval timelines

Increased competition from established players and new entrants in bioprocessing

Potential for price erosion in commoditized product segments

Low ROE indicates potential inefficiencies in capital utilization

Limited cash reserves could restrict growth opportunities if not managed properly

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - the biopharmaceutical industry is somewhat insulated from economic downturns, but overall GDP growth can impact capital expenditures in healthcare.

Interest Rates

Higher interest rates could increase financing costs for Repligen, potentially affecting expansion plans and R&D investments, which may compress valuation multiples.

Credit

minimal - Repligen's low debt levels and strong cash position reduce reliance on credit markets.

Live Conditions
Dow Jones FuturesRussell 2000 FuturesS&P 500 Futures

Profile

growth - investors are likely attracted by the company's strong revenue growth and potential for market expansion.

moderate - historical volatility has been consistent, but recent performance shows a significant return fluctuation.

Key Metrics to Watch
Biopharmaceutical production growth rates
Market share in bioprocessing technologies
R&D spending as a percentage of revenue
Gross margin trends
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.